Summary of Research: Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis

This is a summary of the original article "Safety and effectiveness of concomitant iGlarLixi and SGLT-2i use in people with T2D during Ramadan fasting: a SoliRam study sub-analysis." iGlarLixi is a fixed-ratio combination of insulin glargine 100 U/ml and glucagon like peptide 1 receptor agonist (GLP-1RA) lixisenatide which has demonstrated its effectiveness of improving glycemic parameters and reducing body weight with low risk of hypoglycemia incidence in adults with type 2 diabetes (T2D) who were previously sub-optimally controlled with oral antidiabetic drugs (OADs) alone or in combination with basal insulin or GLP-1RA. This sub-analysis of the SoliRam study assessed the safety and effectiveness of concomitant iGlarLixi and sodium/glucose cotransporter 2 (SGLT-2i) use with or without other OADs in adults with T2D who fasted during Ramadan. Participants were divided into two groups: SGLT-2i-users and SGLT-2i-non-users. The findings showed low incidence of severe and/or symptomatic documented hypoglycemia, improved glycemic control, and body weight benefits, irrespective of SGLT-2i use. No serious adverse events were reported in either group. The sub-analysis concluded that the concomitant iGlarLixi and SGLT-2i therapy, with or without other OADs, was demonstrated to be a safe treatment for people with T2D during Ramadan fasting.